HIV/AIDS Therapy
Ribavarin and stavudine safe in patients coinfected with hepatitis C virus
Published in Hepatitis Weekly, July 7th, 2003
According to published research from France, "a randomized, open-label trial was performed to study virological and intracellular interactions between stavudine and ribavirin in 30 patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)."
"Patients were randomized to receive either interferon and ribavirin or no treatment for HCV infection for three months," and "intracellular peripheral blood mononuclear cells' stavudine-triphosphate (TP) concentrations were assessed" during this time, noted D....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-07-07)
More Articles from Hepatitis Weekly
- Hemophilia
HCV-positive hemophiliacs get comprehensive cancer therapy with surveillance - Hepatocellular Carcinoma
Zinc finger transcription factor defines treatment-sensitive liver cancer - Autoimmune Disease
Proper diagnosis and awareness of autoimmune hepatitis compels better survival - Chronic Hepatitis C
Interferon-alpha(2b) induction with ribavirin posts better results against HCV - Hepatology
Obese rats avoid the development of fatty liver with exercise - Blood Safety
Pakistani injection drug users twice as likely to donate blood - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
